Don’t know about Doctors’ Days or anything, but FWD is showing strong growth, and Ng will be going full blast as a key driver in one category of their HealthyMe product going forward.. A couple of years old story, but the same rally likely continues..
They’ve been picking up all kinds of awards, too.
Roche and Ng probably aren’t competing with each other, but rather complement one another. At best, the NG product could significantly grow the bottom line in two ways – as a paid add-on service and through unrealized treatment costs. It’s an interesting position, even if the stock is currently languishing a bit.
Let’s post this more recent story from The Star if anyone missed it..